Our preclinical genetic and pharmacological intervention studies in primary patient organoids and PDX models of HNSCC, combined with clinical prognostic association studies, provide an encouraging platform to counter therapy resistance against GFR inhibitors by targeting of FER kinase. Here, RAPGEF5 is linked to head and neck squamous cell carcinoma.